Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLBS Caladrius Biosciences		$6.37	$0.38 ▼ $1.24	$26.05M	0.91	522,308 shs	466,373 shs
CNTB Connect Biopharma	$2.06 +17.0%	$1.68	$0.51 ▼ $2.86	$114.79M	-0.09	114,369 shs	194,098 shs
MGNX MacroGenics	$1.77 +4.1%	$1.53	$0.99 ▼ $5.10	$111.88M	1.65	908,740 shs	854,040 shs
SPRO Spero Therapeutics	$2.07 +3.5%	$2.41	$0.51 ▼ $3.22	$116.50M	1.39	1.85 million shs	395,346 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLBS Caladrius Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
CNTB Connect Biopharma	-1.12%	+1.73%	+0.57%	+125.12%	+72.55%
MGNX MacroGenics	-1.16%	+18.06%	+7.59%	+24.00%	-50.72%
SPRO Spero Therapeutics	+1.01%	+7.53%	-9.09%	-22.48%	+45.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	3.3229 of 5 stars	3.8	5.0	0.0	0.0	2.5	2.5	0.0
MGNX MacroGenics	4.3745 of 5 stars	3.3	3.0	0.0	4.4	2.8	4.2	0.0
SPRO Spero Therapeutics	4.0802 of 5 stars	3.3	3.0	0.0	4.7	3.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLBS Caladrius Biosciences	0.00	N/A	N/A	N/A
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	239.81% Upside
MGNX MacroGenics	2.57	Moderate Buy	$3.60	103.39% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	141.55% Upside

Current Analyst Ratings Breakdown

Latest CLBS, CNTB, SPRO, and MGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	MGNX MacroGenics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $5.00
8/13/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
CNTB Connect Biopharma	$1.97M	58.42	N/A	N/A	$1.28 per share	1.61
MGNX MacroGenics	$149.96M	0.75	N/A	N/A	$0.74 per share	2.39
SPRO Spero Therapeutics	$47.98M	2.43	N/A	N/A	$0.58 per share	3.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLBS Caladrius Biosciences	-$27.47M	-$0.41	N/A	N/A	N/A	N/A	-27.24%	-26.08%	N/A
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.57	N/A	N/A	N/A	-21.99%	-40.24%	-14.62%	11/4/2025 (Estimated)
SPRO Spero Therapeutics	-$68.57M	-$0.98	N/A	N/A	N/A	-110.35%	-120.27%	-55.61%	11/13/2025 (Estimated)

Latest CLBS, CNTB, SPRO, and MGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	MGNX MacroGenics	-$0.59	-$0.57	+$0.02	-$0.57	$28.06 million	$22.24 million
8/12/2025	Q2 2025	SPRO Spero Therapeutics	-$0.38	-$0.03	+$0.35	-$0.03	$11.00 million	$14.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLBS Caladrius Biosciences	N/A	22.33	22.33
CNTB Connect Biopharma	0.01	7.24	7.24
MGNX MacroGenics	N/A	5.26	5.02
SPRO Spero Therapeutics	N/A	3.97	3.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLBS Caladrius Biosciences	15.57%
CNTB Connect Biopharma	58.72%
MGNX MacroGenics	96.89%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
CLBS Caladrius Biosciences	2.20%
CNTB Connect Biopharma	22.60%
MGNX MacroGenics	13.00%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLBS Caladrius Biosciences	27	60.58 million	59.25 million	Optionable
CNTB Connect Biopharma	110	55.72 million	43.13 million	Optionable
MGNX MacroGenics	430	63.21 million	54.99 million	Optionable
SPRO Spero Therapeutics	150	56.28 million	53.18 million	Optionable

CLBS, CNTB, SPRO, and MGNX Headlines

Recent News About These Companies

Anson Funds Management LP Has $5.50 Million Position in Spero Therapeutics, Inc. $SPRO

August 26 at 8:11 AM | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above 200-Day Moving Average - Here's What Happened

August 25, 2025 | marketbeat.com

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround

August 19, 2025 | zacks.com

Spero Therapeutics (NASDAQ:SPRO) Releases Earnings Results, Beats Expectations By $0.32 EPS

August 14, 2025 | marketbeat.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 13, 2025 | finanznachrichten.de

Spero Therapeutics Reports Q2 2025 Results and Trial Success

August 13, 2025 | msn.com

Spero Therapeutics Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 12, 2025 | globenewswire.com

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

August 5, 2025 | globenewswire.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLBS, CNTB, SPRO, and MGNX Company Descriptions

Caladrius Biosciences NASDAQ:CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Connect Biopharma NASDAQ:CNTB

$2.06 +0.30 (+17.05%)

Closing price 04:00 PM Eastern

Extended Trading

$2.07 +0.01 (+0.49%)

As of 05:42 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

MacroGenics NASDAQ:MGNX

$1.77 +0.07 (+4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 +0.01 (+0.62%)

As of 05:47 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Spero Therapeutics NASDAQ:SPRO

$2.07 +0.07 (+3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 -0.03 (-1.69%)

As of 05:46 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time